Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | CGAS | Q8N884 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.37 |
| ▸ | CISD1 | Q9NZ45 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | AKR1B1 | P15121 | 4/20 | 0.37 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.37 |
| ▸ | MITF | O75030 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | COMT | P21964 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1614983 | 1.00 | HPGD (0.46) | HPGDCGASHTTSMN1; SMN2HSD17B3 | |
| SCHEMBL2172638 | 0.82 | HSD17B3 (0.60) | HPGDCGASHSD17B3CISD1KMT2A | |
| SCHEMBL2172642 | 0.82 | HSD17B3 (0.60) | HPGDCGASHSD17B3CISD1KMT2A | |
| SCHEMBL12712453 | 0.79 | COMT (0.48) | HPGDCGASSMN1; SMN2ALDH1A1AKR1B1 | |
| SCHEMBL12712456 | 0.79 | COMT (0.48) | HPGDCGASSMN1; SMN2ALDH1A1AKR1B1 | |
| SCHEMBL12712434 | 0.77 | BAG3 (0.51) | HPGDSMN1; SMN2HSD17B3ALDH1A1KMT2A | |
| SCHEMBL12712440 | 0.77 | BAG3 (0.51) | HPGDSMN1; SMN2HSD17B3ALDH1A1KMT2A | |
| SCHEMBL1614016 | 0.77 | SLC2A1 (0.48) | HPGDCGASAKR1B1COMT | |
| SCHEMBL1614013 | 0.77 | SLC2A1 (0.48) | HPGDCGASAKR1B1COMT | |
| SCHEMBL1614944 | 0.76 | AURKA (0.50) | HPGDHTTSMN1; SMN2CISD1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2488027-A1 | THIAZOLIDINEDIONE ENERGY RESTRICTION-MIMETIC AGENTS | The Ohio State University Research Foundation (US) | 2012-08-22 | — | — | EP | claimed |
| WO-2011044548-A1 | THIAZOLIDINEDIONE ENERGY RESTRICTION-MIMETIC AGENTS | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2011-04-14 | — | — | WO | claimed |
| US-20110086895-A1 | THIAZOLIDINEDIONE ENERGY RESTRICTION-MIMETIC AGENTS | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2011-04-14 | — | — | US | claimed |
| US-8383656-B2 | Thiazolidinedione energy restriction-mimetic agents | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2013-02-26 | — | — | US | disclosed |
| US-8383656-B2 | Thiazolidinedione energy restriction-mimetic agents | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2013-02-26 | — | — | US | disclosed |
| US-8383656-B2 | Thiazolidinedione energy restriction-mimetic agents | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2013-02-26 | — | — | US | disclosed |
| WO-2011044548-A1 | THIAZOLIDINEDIONE ENERGY RESTRICTION-MIMETIC AGENTS | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2011-04-14 | — | — | WO | disclosed |
| US-20110086895-A1 | THIAZOLIDINEDIONE ENERGY RESTRICTION-MIMETIC AGENTS | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2011-04-14 | — | — | US | disclosed |
| US-20110086895-A1 | THIAZOLIDINEDIONE ENERGY RESTRICTION-MIMETIC AGENTS | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2011-04-14 | — | — | US | disclosed |
| US-20110086895-A1 | THIAZOLIDINEDIONE ENERGY RESTRICTION-MIMETIC AGENTS | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2011-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110086895-A1 | THIAZOLIDINEDIONE ENERGY RESTRICTION-MIMETIC AGENTS | PCK2, AK2, SIRT6 | HPGD 291/4885CGAS 1301/4885HTT 2112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.